Teva, Merck agree to 2017 date for Vytorin copies

July 11, 2011 | By Tracy Staton
Email LinkedIn
Tools

Teva Pharmaceutical Industries has agreed that it won't sell generic versions of Merck's ($MRK) cholesterol drugs Vytorin and Zetia until 2017, settling patent disputes between the two companies. Merck still faces a patent fight with Mylan over Zetia and Vytorin, however. Report

Filed Under

, , ,

Comments

Press Releases

Featured Jobs